ECNP

LB Pharmaceuticals presented clinical data on its investigational drug LB-102 at the ECNP congress, a major European meeting on neuropsychopharmacology. The company shared findings on the compound, which is being developed as a potential treatment for psychiatric conditions. The presentation gives investors and clinicians an early look at the drug's profile as it advances through development.